Stuart M. Cable

Stuart M. Cable

Stuart M. Cable

Stuart Cable represents as outside general counsel public and private companies involved in the life sciences and technology sector. Mr. Cable also represents private equity and venture sources investing in such companies and investment banks serving such industries. He currently serves as Goodwin’s chair of M&A/Corporate Finance for its Technology and Life Sciences business practices. He previously served as chair of the firm's Corporate Department, as chair of its Hiring Committee, as chair of its Incubator, and as a member of its Executive and Allocations Committees.

Professional Activities

Mr. Cable serves as a member of the President's Leadership Council at Dartmouth College and as chairman emeritus of the Buckingham Browne & Nichols School. He also serves as a member of the Board of Fellows of Harvard Medical School.


Mr. Cable is annually ranked in Chambers USA: America’s Leading Lawyers for Business (Corporate/M&A – Band 1), Chambers Global: The Leading Lawyers for Business (Corporate/M&A) and U.S. News-Best Lawyers (Corporate Law). Global M&A Network has named him one of the world’s top 50 M&A lawyers, recognizing his work advising Onyx Pharmaceuticals in its $10.4 billion purchase by Amgen – a transaction named 2014 Global Major Markets Life Sciences Deal of the Year. He has also been recognized in The Legal 500 U.S. for his M&A work.

Areas of Practice


Mr. Cable represents as outside general counsel to a number of private and public companies, where he counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters. His recent M&A transactions include the sale of Onyx Pharmaceuticals to Amgen ($10.4 billion), the sale of Eloqua to Oracle ($1 billion), the majority sale of Foundation Medicine to Roche ($1 billion), the sale of Idenix to Merck ($3.8 billion), the sale of Pharmacyclics to AbbVie ($21 billion), the sale of Xoom to PayPal ($1 billion), the acquisition of Auspex by Teva Pharmaceuticals ($3.5 billion) and the acquisition of Cord Blood Registry by AMAG Pharmaceuticals ($700 million). In the course of his career, Mr. Cable has negotiated and executed over 300 M&A transactions. Mr. Cable also serves regularly as counsel to issuers in IPOs, follow-on offerings and convertible debt transactions, and acts regularly as counsel for the underwriters in such transactions.



J.D., 1979
Columbia Law School

(Harlan Fiske Stone Scholar)

M.B.A., 1976
Tuck School of Business at Dartmouth
A.B., 1975
Dartmouth College

(magna cum laude)

Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers